Phase 2 × Congenital Abnormalities × Filgrastim × Clear all
NCT00281879 2017-09-27

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

OHSU Knight Cancer Institute

Phase 2 Terminated
200 enrolled 11 charts
NCT01118013 2017-03-24

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant

Alliance for Clinical Trials in Oncology

Phase 2 Terminated
6 enrolled 5 charts
NCT00053196 2016-07-01

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Completed
82 enrolled
NCT00301912 2012-10-02

Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

University of California, San Francisco

Phase 2 Withdrawn
NCT00004899 2012-06-12

Chemotherapy Plus Bone Marrow Transplantation and Filgrastim in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Northwestern University

Phase 2 Completed
NCT00002809 2010-10-01

Bone Marrow Transplant Plus Cyclophosphamide and Total-Body Irradiation in Treating Patients With Hematologic Cancer

Temple University

Phase 2 Completed
10 enrolled
NCT00003116 2010-06-11

High-Dose Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Case Comprehensive Cancer Center

Phase 2 Completed
66 enrolled